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Abstract
Aims. Although shared decision-making (SDM) has the potential to improve health
outcomes, psychiatrists often exclude patients with more severe mental illnesses or more
acute conditions from participation in treatment decisions. This study examines whether
SDM is facilitated by an approach which is specifically adapted to the needs of acutely ill
patients (SDM-PLUS).
Methods. The study is a multi-centre, cluster-randomised, non-blinded, controlled trial of
SDM-PLUS in 12 acute psychiatric wards of five psychiatric hospitals addressing inpatients
with schizophrenia or schizoaffective disorder. All patients fulfilling the inclusion criteria
were consecutively recruited for the trial at the time of their admission to the ward.
Treatment teams of intervention wards were trained in the SDM-PLUS approach through par-
ticipation in two half-day workshops. Patients on intervention wards received group training
in SDM. Staff (and patients) of the control wards acted under ‘treatment as usual’ conditions.
The primary outcome parameter was the patients’ perceived involvement in decision-making
at 3 weeks after study enrolment, analysed using a random-effects linear regression model.
Results. In total, 161 participants each were recruited in the intervention and control group.
SDM-PLUS led to higher perceived involvement in decision-making (primary outcome,
analysed patients n = 257, mean group difference 16.5, 95% CI 9.0–24.0, p = 0.002, adjusted
for baseline differences: β 17.3, 95% CI 10.8–23.6, p = 0.0004). In addition, intervention
group patients exhibited better therapeutic alliance, treatment satisfaction and self-rated medi-
cation compliance during inpatient stay. There were, however, no significant improvements in
adherence and rehospitalisation rates in the 6- and 12-month follow-up.
Conclusions. Despite limitations in patient recruitment, the SDM-PLUS trial has shown that
the adoption of behavioural approaches (e.g. motivational interviewing) for SDM may yield a
successful application to mental health. The authors recommend strategies to ensure effects
are not lost at the interface between in- and outpatient treatment.Trial registration:
The trial was registered at Deutsches Register Klinischer Studien (DRKS00010880).
Introduction
Psychiatrists and patient representatives increasingly see shared decision-making (SDM) with
patients suffering from mental health conditions as an ethical imperative (Drake and Deegan,
2009) which may contribute to greater patient satisfaction and better health outcomes
(Beitinger et al., 2014). However, there is evidence that SDM is rarely implemented in mental
health settings (Hamann et al., 2008; McCabe et al., 2013), especially in acute inpatient units,
where some patients are involuntarily treated (Hamann et al., 2016; Giacco et al., 2018a, b).
Besides the well-known general barriers to SDM (Legare et al., 2008) (e.g. time constraints),
specific mental health factors (or factors that may be exacerbated in mental health settings)
may be responsible for the underuse of SDM. On the patients’ side, these factors include,
among others, a lack of interest in decision-making (e.g. due to depressive or negative symp-
toms) (Hamann et al., 2006; Hamann et al., 2016), a feeling of powerlessness vis-a-vis their
providers (Hamann et al., 2016) or passivity in medical consultations (Hamann et al.,
2014). On the psychiatrists’ side, reservations about implementing SDM are often founded
in doubts about patients’ insight and decisional capacity (Seale et al., 2006; Hamann et al.,
2009; Hamann et al., 2016). Here, psychiatrists might even be afraid to make patient outcomes
worse by sharing decision-making and thereby arrive at bad choices.
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The aim of the present study was to evaluate a complex inter-
vention for the implementation of SDM (shared decision-making
PLUS, i.e. SDM-PLUS (Hamann and Heres, 2014)) that specific-
ally addresses these barriers by expanding SDM techniques with
motivational approaches and by intervening on both sides of
the clinical encounter, i.e. with both patients and providers in
acute treatment settings.
Aim and hypotheses
The aim of the present study was to evaluate the effects of
SDM-PLUS on decision-making patterns on acute psychiatric
wards between psychiatrists and patients with schizophrenia.
We hypothesised that the intervention would lead to professionals
and patients using the skills learned in the SDM-PLUS training,
resulting in a higher perceived involvement of patients. We
argue that better (perceived) involvement of patients in medical
decisions would be a benefit per se (Drake and Deegan, 2009).
However, a higher perceived involvement from the patients’ side
may also have an effect on the therapeutic alliance, paving the
way for better adherence and fewer relapses caused by non-
adherence (Zolnierek and Dimatteo, 2009; Priebe et al., 2011).
Methods
Trial design, randomisation, blinding
The study was designed as a multi-centre, matched-pair cluster-
randomised controlled trial of SDM-PLUS in 12 acute psychiatric
wards of five psychiatric state hospitals addressing inpatients with
schizophrenia or schizoaffective disease (Hamann et al., 2017a).
SDM-PLUS was implemented on the intervention wards, while
on the control wards, treatment as usual (TAU) was continued.
The primary investigators (J.H. and S.H.) determined pairs of
comparable wards (number of patients, distribution of diagnoses,
staff, etc.). For randomisation of wards, a blinded member of our
statistical department generated binary random variables using
the statistical software R. These binary random variables were
then used to assign one of the paired centres to the intervention
group and the other to the control group. A cluster-randomised
design, in which the unit of randomisation is the psychiatric
ward, was seen as necessary to prevent contamination of interven-
tion and control conditions (Craig et al., 2008). In order to min-
imise contamination bias (i.e. staff or patients from control wards
becoming familiar with SDM-PLUS), wards were selected to
ensure that there was no overlap in personnel and no regular
patient transfer between wards.
Due to the nature of the intervention (staff training, patient
training), there was no blinding within intervention wards.
Likewise, a blinding of raters was not applicable because most rat-
ings, including the main outcome measure, were self-ratings.
Participants
All patients fulfilling the inclusion criteria were consecutively
screened for the trial at the time of their admission to the ward.
Inclusion criteria were inpatient status of participating ward, age
18–65 years, diagnosis of schizophrenia or schizoaffective dis-
order (ICD 10: F20/F25), being capable of participating in 60
min group intervention (according to their clinicians’ estimate)
and being able to provide written informed consent. Patients
were excluded if they suffered from mental retardation and had
insufficient proficiency in German to discuss treatment decisions.
Involuntary hospitalisation was not an exclusion criterion.
As it became clear quite early during the study course that
there would be a considerable number of patients dropping out
before the primary outcome, we aimed at compensating for
these dropouts by some over-recruitment.
Intervention and control condition
The SDM-PLUS approach (Hamann and Heres, 2014) was devel-
oped by the authors and some parts of it (e.g. patient training)
had been evaluated in earlier studies (Hamann et al., 2017b).
SDM-PLUS aims to empower health care staff and patients
alike with regard to SDM-specific communication techniques.
For health care staff, the existing approaches to applying SDM
(e.g. Elwyn et al., 2017) were expanded to include patients without
insight or with reduced decisional capacity. Thus, SDM-PLUS
teaches communication techniques derived from motivational
interviewing and negotiation approaches (Hamann and Heres,
2014).
The two principal investigators (J.H. and S.H., both clinical
psychiatrists) provided interactive workshops on SDM-PLUS
techniques to treatment teams (consultants, residents, nurses, psy-
chologists and social workers) working on intervention wards.
The two half-day workshops were based on a power point presen-
tation and written case vignettes for role plays and took place in
the respective psychiatric hospitals. It was mandatory that all phy-
sicians (residents and consultants) of intervention wards and as
many members of the nursing team as possible participated in
both workshops. In addition to these workshops, physicians
were continuously supervised and supported by the study centre
in the form of weekly meetings with the physicians in charge.
In case of staff changes, one-to-one teaching sessions were offered
to new staff members. In the intervention group, all of the partici-
pating physicians took part in the staff training. Additionally,
10–50% of the remaining staff (i.e. nurses, psychologists, social
workers, occupational therapists) participated in the training.
Patients were provided with group training in SDM (Hamann
et al., 2011) and the use of question prompt sheets for ward
rounds and individual consultations. Throughout the study per-
iod, this group training was offered twice a week for all wards
and it was ensured that all intervention group patients partici-
pated at least in two group sessions.
Staff (and patients) from the control wards acted under TAU
conditions but were offered SDM-PLUS training after the end
of the study.
Data obtained
At all time points (baseline, 3 weeks after study enrolment or
discharge, whatever happened first, 3, 6, 9 and 12 months after
discharge), identical data were collected from the intervention
and control groups.
Baseline parameters
For all patients recruited, socio-demographics, diagnosis, illness
severity (Clinical Global Impression (CGI) and Global
Assessment of Functioning (GAF) scores) and data on anamnesis
(previous hospitalisations, duration of illness, etc.) were recorded
at baseline (at study entry). In addition, we administered the
Birchwood Insight Scale (Birchwood et al., 1994) and the patients’
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perception of the current admission using the MacArthur
Admission Experience Survey (O’Donoghue et al., 2013).
Primary outcome
The primary outcome parameter was the patients’ perceived
involvement in decision-making (regarding drug treatment dur-
ing the inpatient stay) using the SDM-Q-9 questionnaire at 3
weeks after enrolment in the study or at discharge (whichever
occurred first). Following Rodenburg-Vandenbussche et al.
(2015), we defined a 15-point difference as clinically meaningful.
Secondary outcomes at 3 weeks after enrolment
Whether or not the intervention also had an influence on the
therapeutic relationship was determined using the Helping
Alliance Scale (patient (HAS-P) and a clinician (HAS-C) version)
(McCabe et al., 2012). Treatment satisfaction was measured using
the Questionnaire on Patients’ Treatment Satisfaction (ZUF8) and
the prevalence of unmet needs on the patients’ side after the inter-
vention was assessed using the Camberwell Assessment of Need
self-report questionnaire (CANSAS-P). For the assessment of
adherence, patients filled out the Medication Adherence Rating
Scale (MARS; Thompson et al., 2000).
Secondary outcomes at 3, 6, 9 and 12 months after discharge
In addition, the aspects of patients’ well-being and quality of life
were addressed using the WHO-5 well-being index and the
EUROHIS-QOL (generic quality of life) (Brähler et al., 2007).
Finally, information on whether or not there had been any read-
missions during the follow-up period was obtained from the
patients’ outpatient psychiatrists.
Statistical analyses
The primary analysis was a comparison of SDM-Q-9 sum scores
at T1 between the intervention and control groups. For the study
to have 80% probability of detecting a mean difference of 15, the
study sought to recruit 23 patients in 12 wards each, giving a total
of 276 patients. This calculation assumed a two-sided significance
level of 5%, a within-cluster standard deviation of 30, intra-cluster
coefficient of 0.04, and 20% dropout.
To assess the effect of the intervention on the continuous pri-
mary outcome, a mixed-effects linear regression model was fitted
with ward (cluster) as a random-effect term and intervention
group as a fixed effect. A significance level of α = 5% was used.
A modified intention-to-treat approach was taken to the analysis,
i.e. patients in intervention clusters were analysed in this group
(if outcome data were available) even if they did not receive all
of the planned intervention. The ICC for the primary outcome
variable was estimated using the variance components of the
mixed-effects model.
Exploratory analyses were performed to assess the effect of the
intervention on the secondary outcome measures. Random-effect
linear models were fitted to the data for group comparisons with
regard to continuous secondary outcome measures, analogous to
the primary analysis. For the binary secondary outcome measure
rehospitalisation, a corresponding logistic mixed-effects model
was used. To account for baseline differences, we performed sen-
sitivity analyses adjusting for all baseline variables with group dif-
ferences of p < 0.25 (illness severity, diagnosis, admission status
and admission experience). As a considerable proportion of
patients dropped out before the main outcome could be obtained,
we additionally did a sensitivity analysis using multiple
imputation methods to predict SDM-Q-9 scores for all patients
with missing values.
As all long-term outcomes were non-significant, we decided to
report only the most important ones in the text. Results on all
outcome measures can be found in the online Supplementary
material.
Ethics, informed consent procedure and trial registration
The trial was approved by the local review board
(Ethikkommission der Technischen Universität München). All
patients gave written informed consent. The trial was registered
at Deutsches Register Klinischer Studien (DRKS00010880) and
the study protocol has been published (Hamann et al., 2017a).
Results
From October 2016 until March 2018, N = 322 inpatients were
recruited for the trial. For participant flow, see Fig. 1
(CONSORT diagram). Among patients screened (n = 871), most
patients were excluded because they did not provide informed
consent (i.e. they refused to participate in the trial (N = 336; inter-
vention/control 206/130)). In addition, N = 94 patients (interven-
tion/control 57/37) were excluded due to insufficient proficiency
in German, followed by severe cognitive impairment (N = 39;
intervention/control 22/17), uncertainty in diagnosed illness
(N = 31; intervention/control 22/9), age above 65 years (N = 20;
intervention/control 9/11), severe aggressive behaviour (N = 12;
intervention/control 9/3). The remaining 18 patients (9 each per
group) were excluded for various reasons (e.g. physical disability
to communicate, etc.).
Baseline data
Patients were on average 42 years old and approximately half were
female. Most patients were suffering from schizophrenia, and
more than a third were admitted involuntarily. Patients had on
average a history of illness of 13 years and had had seven previous
hospitalisations. According to CGI, they were ‘markedly ill’ at
baseline and exhibited a mean GAF score of 37 (see Table 1).
Primary outcome
The intervention yielded a significant ( p = 0.002) effect on the
primary outcome with a mean group difference of 16.5 points
in the SDM-Q-9 sum score (95% confidence interval 9.0–24.0,
T-statistics 4.3, ICC = 0.02), indicating that the intervention
group felt more involved in decision-making (regarding anti-
psychotic medication) than the control group. In the sensitivity
analyses, this result remained stable when accounting for baseline
differences (β 17.3, 95% confidence interval 10.8–23.8, T-statistics
5.2, p = 0.0004) and when using multiple imputation methods
(β 13.4, T-statistics 3.7, 95% confidence interval 6.2–20.6,
p = 0.007).
Secondary outcomes
The positive finding regarding the primary outcome (perceived
involvement in decision-making) is also mirrored in group differ-
ences regarding therapeutic alliance, treatment satisfaction and
self-reported adherence (drug attitudes). Thus, patients in the
intervention group had a better alliance, were more satisfied
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and had better drug attitudes/self-rated adherence than patient in
the control group at 3 weeks after study entry (Table 2).
There were, however, no group differences regarding the other
outcome measures including CGI, GAF and number of unmet
needs. Patients in the two groups also did not differ with regard
to the duration of inpatient stay.
Secondary long-term outcomes
During follow-up, patients and their outpatient psychiatrists were
surveyed with regard to adherence, quality of life and readmis-
sions. Overall, there were no significant group differences on
these dimensions (Table 3).
Discussion
To date, several studies have evaluated interventions that promote
SDM in mental health settings. However, few have addressed very
acutely ill patients or those being treated involuntarily (Giacco
et al., 2018b) and most have had negative results or shown only
modest effects.
The present SDM-PLUS approach for patients with schizo-
phrenia or schizoaffective disorder in very acute mental health
inpatient settings indicates that a complex intervention which
addresses both patients and health care staff changes patients’ per-
ception of therapeutic decision-making during an inpatient stay.
This was true for the primary outcome (patients’ perceived
involvement in decision-making), as well as for therapeutic alli-
ance, treatment satisfaction and self-rated medication compliance.
There were, however, no long-term changes in the period after
discharge.
Limitations
During the study period, consecutive recruitment was adopted to
avoid recruitment bias. However, more patients in the interven-
tion group declined to participate in the trial, which might have
Fig. 1. Participant flow (CONSORT diagram).
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biased our results. However, when accounting for baseline differ-
ences (e.g. in the intervention group, more patients were admitted
involuntarily), group differences (primary and secondary out-
comes) remained stable, indicating that the potential influence
of a recruitment bias is limited.
In addition, the extent to which the proposed strategies were
actually implemented by health care staff might be a potential
methodological limitation, especially as we were not able to
observe a standardised conversation between patients and their
therapists.
Finally, the number of questionnaires returned by patients
during follow-up was rather low, weakening the validity of some
of our secondary outcomes.
Discussion of results
The specific feature of SDM-PLUS is the adoption of the SDM
approach for the more severely ill patients in mental health,
thus, to those patients who might refuse treatment due to a lack
of insight, who might be treated involuntarily or who might
just be too ill in the view of their psychiatrists to reasonably
engage in SDM (Hamann et al., 2009).
The major aim of this trial was to show that SDM-PLUS can
lead to more SDM in this group of patients, as reflected in a
higher perceived involvement of these patients in medical
decision-making. While one might argue that involvement of
patients alone might not constitute a clinical or even financial
Table 1. Baseline data
Intervention (N = 161) Control (N = 161) p value
Age (years, mean, SD) 42.1 (12.9) 41.4 (13.6) 0.61
Gender (female) 84 (52%) 76 (47%) 0.37
Diagnosis F20: 99 (61%)
F25: 52 (32%)
Other F2-diagnosis: 10 (6%)
F20: 115 (71%)
F25: 38 (24%)
Other F2-diagnosis: 8 (5%)
0.21
Involuntary admissions 61 (40%) 41 (28%) 0.03
Legal guardianship 94 (61%) 86 (58%) 0.31
Duration of illness (years, mean, SD) 12.4 (10.3) 13.0 (11.3) 0.62
Previous hospital stays (mean, SD) 6.9 (6.7) 7.6 (7.5) 0.39
CGI (mean, SD) 5.3 (0.9) 5.5 (0.8) 0.04
GAF (mean, SD) 37.7 (13.3) 36.1 (12.4) 0.28
Insight (mean score, SD) 7.7 (2.9) 8.0 (3.1) 0.45
MacArthur Admission Experience (mean score, SD) 2.5 (2.0) 2.1 (1.9) 0.13
Table 2. Secondary outcomes at 3 weeks after enrolment














Helping Alliance Scale (HAS-P)
N = 257
1.09 0.31 1.88 2.75 0.02 1.07 0.39 1.74 3.11 0.01
Helping Alliance Scale (HAS-C)
N = 298
−0.37 −0.97 0.24 −1.18 0.27 −0.42 −0.94 0.11 −1.54 0.15
Treatment satisfaction (ZUF8)
N = 257
2.73 0.74 4.72 2.69 0.02 3.04 1.69 4.39 4.42 0.001
Camberwell Assessment of Need
self-report questionnaire
(CANSAS-P) (Number of items
with unmet needs) N = 256
−0.71 −1.88 0.46 −1.19 0.26 −0.79 −1.91 0.33 −1.38 0.20
Medication Adherence Rating
Scale (MARS) N = 256
1.17 0.41 1.93 3.02 0.01 1.22 0.59 1.86 3.77 0.004
Clinical Global Impression (CGI)
N = 308
−0.29 −0.88 0.30 −0.97 0.36 −0.23 −0.71 0.24 −0.96 0.36
Global Assessment of
Functioning (GAF) N = 308
4.72 −1.76 11.20 1.43 0.18 4.09 −0.79 8.97 1.65 0.13
Duration of inpatient stay (days)
N = 137
8.48 −16.83 33.78 0.66 0.53 11.78 −12.17 35.72 0.96 0.36
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benefit, we claim that the proof of enhanced involvement through
the introduction of the SDM-PLUS approach has at least two
important implications.
First, users have clear expectations towards the mental health
system (Bramesfeld et al., 2007) that include aspects such as dig-
nity and autonomy. The implementation of SDM-PLUS thus may
help implementing these important aspects. Second, our results
show that being highly symptomatic does not prevent patients
from sharing decisions. Neither, patients’ symptoms should pre-
vent psychiatrists from supporting patient autonomy. Based on
our results and other reports (Burn et al., 2019), the argument
can therefore be reasonably made that even in the very acute men-
tal health settings, the desire of many patients to be addressed as
competent individuals (as is in any case ethically required) is pos-
sible and can be implemented.
Our trial has shown that the SDM-PLUS intervention not only
achieved its primary aim but also that important secondary out-
comes during inpatient stay were positively influenced in the
same direction. Thus, treatment satisfaction, therapeutic alliance
and self-reported adherence were also improved in the interven-
tion group. This is in line with findings that interventions for
involuntarily treated inpatients, such as structured patient-centred
care planning, have been shown to improve long-term outcomes
(Giacco et al., 2018a, b).
These positive results were not continued during follow-up
after discharge from the hospital. While improvements during
inpatient treatment are positive achievements per se, the fact
that the effects of the intervention diminished after discharge
should be discussed. One major reason might be that health
care staff in outpatient treatment (i.e. any psychiatrists practising
in the region) was not trained in the SDM-PLUS approach.
Further, patient training alone did not show effects on alliance
and adherence (Hamann et al., 2017b). Finally, the number of
observed cases during follow-up was rather low.
Implications
We believe that the results of the SDM-PLUS trial have several
important implications:
First, an expansion of SDM to the more severely ill patients in
mental health is possible. This is good news for all patients being
treated on closed wards, because it invalidates general excuses for
not engaging these patients in medical decision-making. Second,
expansions of SDM may need to adopt behavioural approaches
(such as motivational interviewing) to be successful with some
patients. In addition, training patients may also be necessary to cre-
ate a ward atmosphere congenial to SDM. Third, the SDM
approach appears to change important patterns during inpatient
treatment. However, while inpatients transit to outpatient treatment
(and thereby change health care staff), positive effects are lost.
Strategies for ensuring a continuation of SDMmeasures at the inter-
face between in- and outpatient treatment need to be developed.
Finally, the SDM-PLUS approach (as all previous SDM
approaches) does not yet account for the important role (infor-
mal) caregivers may play for the long-term course of mental ill-
nesses. Studies addressing the prospects and modes of caregiver
involvement in SDM (Hamann and Heres, 2019) are therefore
of great interest, as their ‘triadic’ inclusion may boost the effects
of SDM.
Supplementary material. The supplementary material for this article can
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Data. The datasets generated during and/or analysed during the current study
are available from the corresponding author on reasonable request.
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